Tandem Diabetes Care (NASDAQ:TNDM) Upgraded by Leerink Partnrs to “Outperform”

Leerink Partnrs upgraded shares of Tandem Diabetes Care (NASDAQ:TNDM) from a market perform rating to an outperform rating in a research report report published on Thursday, Zacks.com reports.

Other analysts also recently issued research reports about the company. Citigroup raised their price objective on Tandem Diabetes Care from $31.00 to $38.00 and gave the stock a neutral rating in a research report on Wednesday, April 3rd. SVB Leerink upgraded Tandem Diabetes Care from a market perform rating to an outperform rating and raised their price objective for the stock from $34.00 to $45.00 in a research report on Thursday. Stifel Nicolaus raised their price objective on Tandem Diabetes Care from $37.00 to $40.00 and gave the stock a buy rating in a research report on Tuesday, April 23rd. Finally, StockNews.com upgraded Tandem Diabetes Care from a sell rating to a hold rating in a research report on Friday, April 19th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Tandem Diabetes Care currently has a consensus rating of Moderate Buy and a consensus price target of $39.45.

Tandem Diabetes Care Price Performance

Shares of NASDAQ:TNDM opened at $35.24 on Thursday. The business has a 50 day moving average price of $30.96 and a 200 day moving average price of $25.42. Tandem Diabetes Care has a twelve month low of $13.82 and a twelve month high of $40.74. The company has a market cap of $2.28 billion, a price-to-earnings ratio of -10.24 and a beta of 1.12. The company has a quick ratio of 3.02, a current ratio of 3.83 and a debt-to-equity ratio of 0.91.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. The business had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. Research analysts predict that Tandem Diabetes Care will post -1.62 earnings per share for the current year.

Hedge Funds Weigh In On Tandem Diabetes Care

Hedge funds have recently modified their holdings of the stock. RiverPark Advisors LLC acquired a new position in shares of Tandem Diabetes Care in the 4th quarter worth approximately $27,000. MCF Advisors LLC raised its holdings in shares of Tandem Diabetes Care by 79.3% in the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock worth $36,000 after buying an additional 445 shares in the last quarter. Signaturefd LLC raised its holdings in shares of Tandem Diabetes Care by 871.8% in the 4th quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock worth $50,000 after buying an additional 1,517 shares in the last quarter. Arcadia Investment Management Corp MI raised its holdings in shares of Tandem Diabetes Care by 141.6% in the 1st quarter. Arcadia Investment Management Corp MI now owns 1,851 shares of the medical device company’s stock worth $66,000 after buying an additional 1,085 shares in the last quarter. Finally, GAMMA Investing LLC acquired a new stake in Tandem Diabetes Care during the 4th quarter valued at $73,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.